| scholarly article | Q13442814 |
| P50 | author | Luke Norton | Q51373612 |
| Ralph A. DeFronzo | Q58689309 | ||
| P2093 | author name string | G Clarke | |
| R E J Ryder | |||
| M Abdul-Ghani | |||
| R Chilton | |||
| P2860 | cites work | Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis | Q24655666 |
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study | Q28281870 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. | Q30903369 | ||
| Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus | Q33786881 | ||
| Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
| Thiazolidinediones | Q34346862 | ||
| Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy | Q34430674 | ||
| Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study | Q34494252 | ||
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone | Q34543009 | ||
| Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial | Q34572519 | ||
| Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study | Q34626189 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials | Q34686089 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes | Q35548033 | ||
| Dapagliflozin lowers plasma glucose concentration and improves β-cell function | Q35578244 | ||
| Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
| Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy | Q36047253 | ||
| Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study' | Q36073447 | ||
| The effects of thiazolidinediones on blood pressure levels - a systematic review | Q36545395 | ||
| Pioglitazone after Ischemic Stroke or Transient Ischemic Attack | Q36953272 | ||
| Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
| Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis | Q37106685 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates | Q37251096 | ||
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors | Q37505281 | ||
| Risk of fractures with glitazones: a critical review of the evidence to date | Q37520986 | ||
| Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients | Q37524302 | ||
| Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis | Q37683205 | ||
| Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. | Q37878715 | ||
| Thiazolidinediones and fracture risk in patients with Type 2 diabetes | Q37889370 | ||
| Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 2: ST-segment elevation myocardial infarction | Q37961085 | ||
| Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus | Q38005020 | ||
| Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus | Q38408749 | ||
| Pharmacokinetics of Empagliflozin and Pioglitazone After Coadministration in Healthy Volunteers | Q38410283 | ||
| Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis | Q38417421 | ||
| Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial | Q38473723 | ||
| Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus | Q38638523 | ||
| Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion | Q39554276 | ||
| Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes | Q41107308 | ||
| Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. | Q41895967 | ||
| Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes | Q42518121 | ||
| Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients | Q44018167 | ||
| Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial | Q44251536 | ||
| Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms | Q44272913 | ||
| Thiazolidinediones and blood lipids in type 2 diabetes | Q44542266 | ||
| A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors | Q45124693 | ||
| Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. | Q46024732 | ||
| Thiazolidinedione use and the risk of fractures. | Q46052082 | ||
| Impact of peripheral arterial disease in patients with diabetes--results from PROactive (PROactive 11). | Q46552257 | ||
| A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia | Q46570674 | ||
| Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption | Q46592677 | ||
| Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes | Q46966704 | ||
| Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. | Q51335341 | ||
| Rosiglitazone decreases albuminuria in type 2 diabetic patients. | Q51463962 | ||
| Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
| The effect of pioglitazone on the liver: role of adiponectin. | Q51488911 | ||
| Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. | Q51497865 | ||
| Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. | Q51552529 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 454-462 | |
| P577 | publication date | 2016-04-06 | |
| P1433 | published in | Diabetes, Obesity and Metabolism | Q5270109 |
| P1476 | title | Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor | |
| P478 | volume | 18 |
| Q88758014 | A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice |
| Q39000587 | Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies |
| Q92813444 | Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial |
| Q100946503 | Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors |
| Q38778064 | Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus |
| Q47696671 | Pharmacological management of type 2 diabetes: what's new in 2017? |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q38708422 | The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia |
| Q89881026 | The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety |
| Q90781399 | The tumor suppressor TMEM127 regulates insulin sensitivity in a tissue-specific manner |
Search more.